Director Dealing-PHYSIOMICS PLC

Director Dealing-PHYSIOMICS PLC

Director Dealing

The Company announces that Dr Christophe Chassagnole, Chief Operating Officer of Physiomics, has transferred, for no consideration,  500,000 ordinary shares of 0.4p each in the Company held in certificated form ("Ordinary Shares") to his nominee account with Interactive Investor Services Limited. The Ordinary Shares remain beneficially owned by Dr Chassagnole.

Accordingly, Dr Chassagnole's total holding in the Company will remain unchanged at 1,102,723 Ordinary Shares, representing approximately 0.81 per cent. of the Company's issued share capital.

The Company's LEI is 213800A71DSZ6ABMTQ91

PDMR Notification Forms

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Christophe Chassagnole

2.

Reason for the Notification

a)

Position/status

Executive Director, COO

b)

Initial notification/amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Physiomics plc

b)

LEI

 213800A71DSZ6ABMTQ91

4.

Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Physiomics plc Ordinary Shares

Identification code

ISIN:  GB00BDR6W943

b)

Nature of the Transaction

Transfer of securities held in paper share certificates to nominee account Interactive Investor Services Nominees Limited.

c)

Price(s) and volume(s)

Dr Christophe Chassagnole

Price(s)

Volume(s)

N/A

500,000

d)

Aggregated information

-       Aggregated volume

 

-       Price

 

 

500,000

N/A

e)

Date of the transaction

14 July 2023

f)

Place of the transaction

Off market transaction

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 100 projects, involving over 50 targets and 75 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

No Comments

Post a Comment